United States - English - NLM (National Library of Medicine)

greenstone llc - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g - sucralfate is indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate is contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g - sucralfate tablets, usp are indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate tablets are contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Ireland - English - HPRA (Health Products Regulatory Authority)

jurox (ireland) limited - alfaxalone - solution for injection - 10 milligram(s)/millilitre - alfaxalone

Ireland - English - HPRA (Health Products Regulatory Authority)

jurox (ireland) limited - alfaxalone - solution for injection - 10 milligram(s)/millilitre - alfaxalone

Ireland - English - HPRA (Health Products Regulatory Authority)

jurox (ireland) limited - alfaxalone - solution for injection - 10 milligram(s)/millilitre - alfaxalone

New Zealand - English - Ministry for Primary Industries

zoetis new zealand limited - alfaxalone - alfaxalone 10 g/litre - anaesthetic

New Zealand - English - Ministry for Primary Industries

zoetis new zealand limited - alfaxalone - alfaxalone 10 g/litre - anaesthetic

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g - sucralfate is indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. there are no known contraindications to the use of sucralfate.

United States - English - NLM (National Library of Medicine)

jurox pty. limited - alfaxalone (unii: bd07m97b2a) (alfaxalone - unii:bd07m97b2a) - alfaxalone 10 mg in 1 ml - indications alfaxan is indicated for the induction and maintenance of anesthesia and for induction of anesthesia followed by maintenance with an inhalant anesthetic, in cats and dogs. contraindications: alfaxan is contraindicated in cats and dogs with a known sensitivity to alfaxalone or its components, or when general anesthesia and/or sedation are contraindicated. drug abuse and dependence: controlled substance: alfaxan contains alfaxalone, a neurosteroid anesthetic and a class iv controlled substance. abuse: alfaxalone is a central nervous system depressant that acts on gaba receptor associated chloride channels, similar to the mechanism of action of schedule iv sedatives such as benzodiazepines (diazepam and midazolam), barbiturates (phenobarbital and methohexital) and fospropofol. in a drug discrimination behavioral test in rats, the effects of alfaxalone were recognized as similar to those of midazolam. these biochemical and behavioral data suggest that alfaxalone has an abuse potential similar to oth

United States - English - NLM (National Library of Medicine)

stat rx usa llc - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g - sucralfate is an α-d-glucopyranoside, β-d-fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex. tablets for oral administration contain 1 g of sucralfate. also contain: povidone, magnesium stearate, and colloidal silicon dioxide. therapeutic category: antiulcer. sucralfate is only minimally absorbed from the gastrointestinal tract. the small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine. although the mechanism of sucralfate’s ability to accelerate healing of duodenal ulcers remains to be fully defined, it is known that it exerts its effect through a local, rather than systemic, action. the following observations also appear pertinent: - studies in human subjects and with animal models of ulcer disease have shown that sucralfate forms an ulcer-adherent complex with proteinaceous exudate at the ulcer site. - in vitro , a sucralfate-albumin film provides a barrier to diffusion of hydrogen ions. - in human subjects, sucralfate given in doses recomme